MedPath

Prostate Embolization for Acute Urinary Retention Study

Not Applicable
Conditions
Prostatic Hypertrophy, Benign
Interventions
Device: Bead Block
Registration Number
NCT02689830
Lead Sponsor
ClinSearch
Brief Summary

The purpose of this study is to assess the feasibility and safety of Prostate Artery Embolization (PAE) in patients suffering of Acute Urinary Retention (AUR) in the context Benign Prostatic Hypertrophy (BPH).

Detailed Description

This is an open-label prospective, multicenter (centralized procedure), single arm, sequentially enrolling study. Twenty subjects will be enrolled in the study.

Patient will be referred by the attending urologists after failure of the currently recommended approach of Trial WithOut Catheter (TWOC) and alpha-adrenergic receptor (AR) blockers.

It is expected that all AUR cases referred to the local urological clinic will be considered for inclusion in the trial. A trial log book will be completed by the referring local urologist in order to obtain preliminary data on the applicability of the trial to all AUR comers in the institution. This log book will be limited to a very simple questionnaire to ensure high rate of completion by the attending resident/fellow (Patients age, size of prostate, previous Benign Prostate Hypertrophy symptoms, renal function). It will be used in order to assess the external validity of this first phase trial and will be a help to design the potential next step trial.

When a patient will present with AUR in the corresponding urological clinic, the PI and Clinical research coordinator will be informed by a short text message, fax or e-mail in order to prepare the following process.

Patient will be informed by the urologist of the ongoing research project. In summary, this will consist in informing the patient that the first step is TWOC and in case of failure of TWOC several options are offered including PAE in the trial setting. Inclusion of the patient will considered only in case of failure of TWOC.

If the patient is willing to participate, patient will be seen in clinic by the Principal Investigator or co-investigator in order to inform him of the protocol and obtain signed informed consent.

PAE will be scheduled upon the first contact to make sure that PAE is performed in a short delay following failure of TWOC. The goal is to perform PAE in the week following recatheterization. For practical reasons this delay might be extended and will be recorded in the Case Report Form.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
20
Inclusion Criteria
  • AUR Patients presenting with a first episode of AUR related to BPH (no matter if previously known or not) AND
  • Failure of at least one TWOC AND
  • Prostate size > or = 50 ml (ultrasound measurement)
Exclusion Criteria
  • Known hypocontractile bladder
  • AUR related to other causes (Acute prostatitis or documented Prostate cancer)
  • Severe iodine allergy
  • Known prostate cancer
  • Known ongoing acute or chronic prostatitis
  • On-going acute pyelonephritis or septicemia from urinary origin
  • Patient refusing PAE
  • Severe renal failure (creatinine Clearance < 20 ml/min (MDRD)
  • Contra-indication to AR blockers (postural hypotension micturition syncope)
  • Contra-indication to anticoagulants
  • Patient catheterized with a suspubian catheter
  • Patient <18
  • Patients who are prisoners
  • Patients who are mentally incapacitated
  • Patients participating in an investigational study involving the peripheral vasculature
  • Patients unable or unwilling to provide written informed consent
  • Patients ineligible for pelvic angiography and embolization including severe atheromatous condition or any anatomical condition

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Bead Block microspheresBead BlockProstate embolization
Primary Outcome Measures
NameTimeMethod
Procedure success6 months after PAE

percentage of patients free of Foley and/or any prostate surgery

Secondary Outcome Measures
NameTimeMethod
Number of cumulated hospitalization daysbetween PAE and 6 months post-PAE
Comparison of the number of Benign Prostate Hypertrophy medicationbefore and 6 months after PAE
Percentage of procedure related or contributed complications1 week after PAE
Percentage of immediate technical success of embolization5 minutes after the beginning of the procedure

Percentage of bilateral embolization

Comparison of International Prostate Symptom Scorebetween pre-PAE and 6 months post-PAE
Comparison of Quality of Life Questionnairebetween pre-PAE and 6 months post-PAE
Time of re-catheterization6 months after PAE
Time until TransUrethral Resection of the Prostate or open surgery6 months
Cumulative number of days with bladder catheterbetween PAE and 6 months post-PAE
Cumulative number of per-procedure angiographic and clinical complications24 hours after PAE

according to the Society of Interventional Radiology and Dindo classifications

Comparison of International Index of Erectile Functionbetween pre-PAE and 6 months post-PAE
Number of re-catheterization6 months after PAE
Total number of consultationsbetween PAE and 6 months post-PAE

consultations with interventional radiologist and/or urologist

Immediate technical success of embolization5 minutes after the beginning of the procedure

percentage of unilateral versus percentage of bilateral embolization

Number of patients free of bladder catheterbetween PAE and 6 months post-PAE
Prostate volume6 months

Measured with MRI or ultrasound

Trial Locations

Locations (3)

Hôpital Saint-Louis

🇫🇷

Paris, France

Hôpital Cochin

🇫🇷

Paris, France

Hôpital Européen Georges Pompidou

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath